Yuhan Corporation Aims for 30% Shareholder Return Rate by 2027

"1% Treasury Share Retirement by 2027"

Yuhan Corporation is continuing its shareholder return policy aimed at enhancing shareholder value.

Yuhan Corporation logo image. Yuhan Corporation

According to Yuhan Corporation on January 14, the company plans to achieve an average shareholder return rate of over 30% from 2025 to 2027. To this end, the company will retire 1% of its treasury shares by 2027 and will continue to increase its dividend per share.

Currently, Yuhan Corporation’s dividend payout ratio stands at 53%, which is significantly higher than the industry average of around 10%. As of last year, the company’s total dividend payout was in the 30 billion won range. It paid 500 won per common share and 510 won per preferred share.

Interest in Yuhan Corporation’s dividend policy has recently increased considerably. This is due to the spotlight on the efficacy of the combination therapy of the new lung cancer drug Leclaza (ingredient: lazertinib) and Johnson & Johnson’s Rybrevant (ingredient: amivantamab).

The Leclaza combination therapy was listed as the preferred regimen by the National Comprehensive Cancer Network (NCCN) in November last year, establishing itself as a standard clinical guideline. In December of the same year, the subcutaneous (SC) formulation of Rybrevant received approval from the U.S. Food and Drug Administration (FDA), raising expectations for increased global sales. Yuhan Corporation receives royalties of more than 10% of net global sales of Leclaza from Johnson & Johnson.